聚乙二醇干扰素α-2a治疗羟基脲耐药或不耐受的真性红细胞增多症或原发性血小板增多症
MPD-RC-111 是一项国际多中心 2 期试验,评估聚乙二醇干扰素α-2a(PEG)在高危 ET 或 PV 且对羟基脲(HU)耐药或不耐受患者中的疗效。PEG 对 HU 耐药/不耐受的 ET 或 PV 有效,不良事件多可管理,仅 13.9% 因不良事件停药。
要点
- PEG 对 HU 耐药/不耐受的高危 ET 和 PV 患者有效,12 个月 ORR 分别为 69.2% 和 60%。
- 不良事件常见但多可管理,仅 13.9% 患者因不良事件停用 PEG。
核心结论
- PEG 是既往对 HU 耐药和/或不耐受的 ET 或 PV 患者的有效治疗。
研究设计与样本
- MPD-RC-111 是研究者发起的国际多中心 2 期试验,评估 PEG 诱导完全和部分血液学缓解的能力,纳入 65 例 ET 和 50 例 PV 患者。
主要发现
- 12 个月总缓解率(CR/PR)在 ET 患者为 69.2%(CR 43.1%,PR 26.2%),在 PV 患者为 60%(CR 22%,PR 38%)。
- 达到 CR 的患者 JAK2V617F 变异等位基因分数中位绝对下降 -6%(范围 -84% 至 47%),而 PR 或 NR 患者为 +4%(范围 -18% 至 56%)。
- 治疗相关不良事件发生率显著,但大多可管理,因不良事件停用 PEG 者仅占 13.9%。
临床怎么用
- 对于 HU 耐药或不耐受的高危 ET 或 PV 患者,可考虑使用 PEG 治疗。
- CALR 突变 ET 患者可能从 PEG 治疗中获得更高的完全缓解率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To further define the role of rIFN-α, we investigated the outcomes of pegylated-rIFN-α2a (PEG) therapy in ET and PV patients previously treated with hydroxyurea (HU). The Myeloproliferative Disorders Research Consortium (MPD-RC)-111 study was an investigator-initiated, international, multicenter, phase 2 trial evaluating the ability of PEG therapy to induce complete (CR) and partial (PR) hematologic responses in patients with high-risk ET or PV who were either refractory or intolerant to HU. The study included 65 patients with ET and 50 patients with PV. The overall response rates (ORRs; CR/PR) at 12 months were 69.2% (43.1% and 26.2%) in ET patients and 60% (22% and 38%) in PV patients. CR rates were higher in CALR-mutated ET patients (56.5% vs 28.0%; P = .01), compared with those in subjects lacking a CALR mutation. The median absolute reduction in JAK2V617F variant allele fraction was -6% (range, -84% to 47%) in patients achieving a CR vs +4% (range, -18% to 56%) in patients with PR or nonresponse (NR). Therapy was associated with a significant rate of adverse events (AEs); most were manageable, and PEG discontinuation related to AEs occurred in only 13.9% of subjects. We conclude that PEG is an effective therapy for patients with ET or PV who were previously refractory and/or intolerant of HU. This trial was registered at www.clinicaltrials.gov as #NCT01259856.
引用
- Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019. PMID: 31515250. doi:10.1182/blood.2019000428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。